The bidirectional effect of prelimbic 5-hydroxytryptamine type-4 (5-HT4) receptors on ACPA-mediated aversive memory impairment in adult male Sprague-Dawley rats

Document Type : Original Article


1 Institute for Cognitive Science Studies, Tehran, Iran

2 Department of Basic Sciences, Campus of Shahid Bahonar, Farhangian University of Shiraz, Shiraz, Iran

3 Department of Pharmacology, School of Medicine and Department of Neuroscience, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran

4 Cognitive and Neuroscience Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

5 Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran

6 Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

7 School of Cognitive Sciences, Institute for Research in Fundamental Sciences, Tehran, Iran


Objective(s): This study aimed at investigating the effect of serotonergic 5-HT4 receptor agonist/antagonist on memory consolidation deficit induced by ACPA (a potent, selective CB1 cannabinoid receptor agonist) in the pre-limbic (PL) cortex.
Materials and Methods: We used the step-through passive avoidance test to evaluate memory consolidation of male Sprague-Dawley (SD) rats. Bilateral post-training microinjections of the drugs were done in a volume of 0.6 μl/rat into the PL area (0.3 μl per side).
Results: The results showed a significant interaction between RS67333 hydrochloride (5-HT4 receptor agonist) or RS23597-190 hydrochloride (5-HT4 receptor antagonist) and ACPA on consolidation of aversive memory. RS67333 hydrochloride (0.5 μg/rat) enhanced consolidation of memory and its co-administration at the ineffective dose of 0.005 μg/rat with ineffective (0.001 μg/rat) or effective (0.1 μg/rat) doses of ACPA improved and prevented impairment of memory caused by ACPA, respectively. In other words, RS67333 had a bidirectional effect on ACPA-caused amnesia. While RS23597-190 hydrochloride had no effect on memory at the doses used (0.005, 0.01, 0.1, or 0.5 μg/rat); but its concomitant use with an effective dose of ACPA (0.1 μg/rat) potentiated amnesia. None of the drugs had an effect on locomotor activity.
Conclusion: This study revealed that activation or deactivation of the 5-HT4 receptors in the PL may mediate the IA memory impairment induced by ACPA indicating a modulatory role for the 5-HT4 serotonergic receptors.


1. Green AR. Neuropharmacology of 5‐hydroxytryptamine. Br J Pharmacol 2006; 147:S145-S152.
2. Dhonnchadha BÁN, Cunningham KA. Serotonergic mechanisms in addiction-related memories. Behav Brain Res 2008; 195:39-53.
3. Haj-Dahmane S, Shen RY. Modulation of the serotonin system by endocannabinoid signaling. Neuropharmacology 2011; 61:414-420.
4. King MV, Marsden CM, Fone KCF. A role for the 5-HT1A, 5-HT4 and 5-HT6 receptors in learning and memory. Trends Pharmacol Sci 2008 29:482–492.
5. Bockaert J, Claeysen S, Compan V, Dumuis A. 5-HT4 Receptors. Curr Drug Targets CNS Neurol Disord 2004; 3:39-51.
6. Murphy SE, Wright LC, Browning M, Cowen PJ, Harmer CJ. A role for 5-HT4 receptors in human learning and memory. Psychol Med 2019:1-9.
7. Cai X, Flores-Hernandez J, Feng J, Yan Z. Activity-dependent bidirectional regulation of GABAA receptor channels by the 5-HT4 receptor-mediated signalling in rat prefrontal cortical pyramidal neurons. J Physiol 2002; 540.3:743–759.
8. Perez-Garcia G, Meneses A. Memory formation, amnesia, improved memory and reversed amnesia: 5-HT role. Behav Brain Res 2008; 195:17-29.
9. Ahmad I, Nirogi R. 5-HT4 Receptor agonists for the treatment of alzheimer’s disease. Neurosci Med 2011; 2:87-92.
10. Orsetti M, Dellarole A, Ferri S, Ghi P. Acquisition, retention, and recall of memory after injection of RS67333, a 5-HT4 receptor agonist, into the nucleus basalis magnocellularis of the rat. Learn Mem 2003; 10:420-426.
11. Lucas G, Compan V, Charnay Y, Neve RL, Nestler EJ, Bockaert J, et al. Frontocortical 5-HT4 receptors exert positive feedback on serotonergic activity: Viral transfections, subacute and chronic treatments with 5-ht4 agonists. Biol Psychiatry 2005; 15:918-925.
12. Feng J, Cai X, Zhao JH, Yan Z. Serotonin receptors modulate GABAA receptor channels through activation of anchored protein kinase C in prefrontal cortical neurons. J Neurosci 2001; 21: 6502–6511.
13. Euston DR, Gruber AJ, McNaughton BL. The role of medial prefrontal cortex in memory and decision making. Neuron 2012; 76:1056-1070.
14. Vertes RP. Interactions among the medial prefrontal cortex, hippocampus and midline thalamus in emotional and cognitive processing the rat. Neurosci 2006; 142 1–20.
15. Stern CAJ, Gazarini L, Vanvossen AC, Hames MS, Bertoglio LJ. Activity in prelimbic cortex subserves fear memory reconsolidation over time. Learn Mem 2014; 21:14-20.
16. Sotres-Bayon F, Sierra-Mercado D, Pardilla-Delgado E, Quirk GJ. Gating of fear in prelimbic cortex by hippocampal and amygdala inputs. Neuron 2012; 76:804–812.
17. Zhang Y, Fukushima H, Kida S. Induction and requirement of gene expression in the anterior cingulate cortex and medial prefrontal cortex for the consolidation of inhibitory avoidance memory. Mol Brain 2011; 4:1-11.
18. Lichtman AH, Varvel SA, Martin BR. Endocannabinoids in cognition and dependence. Prostaglandins Leukot Essent Fatty Acids 2002; 66:269–285.
19. Tan H, Lauzon NM, Bishop SF, Chi N, Bechard M, Laviolette SR. Cannabinoid transmission in the basolateral amygdala modulates fear memory formation via functional inputs to the prelimbic cortex. J Neurosci 2011; 31:5300-5312.
20. Egerton A, Allison C, Brett RR, Pratt JA. Cannabinoids and prefrontal cortical function: insights from preclinical studies. Neurosci Biobehav Rev 2006; 30:680-695.
21. Maejima T, Masseck OA, Mark MD, Herlitze S. Modulation of firing and synaptic transmission of serotonergic neurons by intrinsic G protein-coupled receptors and ion channels. Front Integr Neurosci 2013 7:1-15.
22. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004; 47:345-358
23. Haring M, Marsicano G, Lutz B, Monory K. Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice. Neuroscice 2007; 146:1212–1219.
24. Hermann H, Marsicano G, Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neurosci 2002; 109:451-460.
25. Ferreira SG, Teixeira FM, Garcao P, Agostinho P, Ledent C, Cortes L. Presynaptic CB (1) cannabinoid receptors control frontocorticals serotonin and glutamate release – species differences. Neurochem Int 2012; 61:219–226.
26. Balazsa T, Biro J, Gullai N, Ledent C, Sperlagh B. CB1-cannabinoid receptors are involved in the modulation of non-synaptic [3H]serotonin release from the rat hippocampus. Neurochem Int 2008; 52:95-102.
27. Aso E, Renoir T, Mengod G, Ledent C, Hamon M, Maldonado R, et al. Lack of CB1 receptor activity impairs serotoninergic negative feedback. J Neurochem 2009; 109:935–944.
28. Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, et al. The CB1 receptor antagonist SR 141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Pharmacol Biochem Behav 2003; 138:544–553.
29. Zavitsanou K, Wang H, Dalton VS, Nguyen V. Cannabinoid administration increases 5HT1A receptor binding and mRNA expression in the hippocampus of adult but not adolescent rats. Neuroscince 2010; 169:315–324.
30. Moranta D, Esteban S, Garcia-Sevilla JA. Chronic treatment and withdrawal of the cannabinoid agonist WIN 55,212-2 modulate the sensitivity of presynaptic receptors involved in the regulation of monoamine syntheses in rat brain. Naunyn-Schmiedeberg’s Arch Pharmacol 2009; 379:61–72.
31. Best AR, Regehr WG. Serotonin evokes endocannabinoid release and retrogradely suppresses excitatory synapses. Neuroscince 2008; 28:6508–6515.
32. N.R.C. Guide for the Care and Use of Laboratory Animals. Eighth Edition ed. Washington, DC: The National Academies Press; 2011.
33. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 6th ed. London,UK: Academic Press; 2007.
34. Rasekhi K, Oryan S, Nasehi M, Zarrindast MR. Involvement of the nucleus accumbens shell glutamatergic system in ACPA-induced impairment of inhibitory avoidance memory consolidation. Behav Brain Res 2014; 269:28-36.
35. Ahmadi-Mahmoodabadi N, Nasehi M, Emam Ghoreishi M, Zarrindast M-R. Synergistic effect between prelimbic 5-HT3 and CB1 receptors on memory consolidation deficit in adult male Sprague–Dawley rats: An isobologram analysis. Neuroscience 2016; 317:173–183.
36. Ogren SO, Stiedl O. Passive Avoidance. Encyclopedia of Psychopharmacol 2015:1220-1228.
37. Ueki A, Miwa Ch, Miyoshi K. Impairment in the acquisition of passive and active avoidance learning tasks due to bilateral entorhinal cortex lesions. Neurol Sci 1994; 125:14-21.
38. Chegini HR, Nasehi M, Zarrindast MR. Differential role of the basolateral amygdala 5-HT3 and 5-HT4 serotonin receptors upon ACPA-induced anxiolytic-like behaviors and emotional memory deficit in mice. Behav Brain Res 2014; 261:114– 126.
39. Lamirault L, Simon H. Enhancement of place and object recognition memory in young adult and old rats by RS 67333, a partial agonist of 5-HT4 receptors. Neuro Pharmacol 2001; 41:844–853.
40. Meneses A. Stimulation of 5-HT1A, 5-HT1B, 5-HT2A/2C, 5-HT3 and 5-HT4 receptors or 5-HT uptake inhibition: short- and long-term memory. Behav Brain Res 2007; 184:81-90.
41. Freret T, Bouet V, Quiedeville A, Nee G, Dallemagne P, Rochais C, et al. Synergistic effect of acetylcholinesterase inhibition (donepezil) and 5-HT(4) receptor activation (RS67333) on object recognition in mice. Behav Brain Res 2012; 230:304-308.
42. Nasehi M, Davoudi K, Ebrahimi-Ghiri M, Zarrindast M-R. Interplay between serotonin and cannabinoid function in the amygdala in fear conditioning. Brain Res 2016; 1636:142-151.
43. Nasehi M. The modulatory effect of CA1 5HT 4 receptors on memory acquisition deficit induced by harmaline. J Paramed Sci 2014; 5:61-71.
44. Polter AM, Li X. 5-HT1A receptor-regulated signal transduction pathways in brain. Cell Signal 2010; 22:1406-1412.
45. Bockaert J, Claeysen S, Compan V, Dumuis A. 5-HT4 receptors: History, molecular pharmacology and brain functions. Neuropharmacology 2008; 55:922-931.
46. Steven CL, Yan L, Alan LP, Elena D, Gennady S, Connie S. Serotonergic regulation of prefrontal cortical circuitries involved in cognitive processing: A review of individual 5 HT receptor mechanisms and concerted effects of 5 HT receptors exemplified by he multimodal antidepressant vortioxetine. ACS Chem Neurosci 2015; 6:970−986.
47. Seyedabadi M, Fakhfouri G, Ramezani V, Mehr SE, Rahimian R. The role of serotonin in memory: interactions with neurotransmitters and downstream signaling. Exp Brain Res 2014; 232:723-738.
48. Pytliak M, Vargova V, Mechirova V, Felsoci M. Serotonin receptors from molecular biology to clinical applications. Physiol Res 2011; 60:15–25.
49. Coupar IM, Desmond PV, Irving HR. Human 5-HT4 and 5-HT7 Receptor splice variants: Are they important. Curr Neuropharmacol 2007; 5:224-231.
50. Claeysen S, Sebben M, Becamel C, Bockaert J, Dumuis A. Novel brain-specific 5-HT4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. Mol Pharmacol 1999; 55:910-920.
51. Pindon A, Hecke GV, Gompel PV, Lesage AS, Leysen JE, Jurzak M. Differences in signal transduc-tion of two 5-HT4 receptor splice variants: compound specificity and dual coupling with gαs and gαi/o-proteins. Molecular Pharmacology 2002; 61:85-96.
52. Ji LL, Peng JB, Fu CH, Cao D, Li D, Tong L, et al. Activation of Sigma-1 receptor ameliorates anxiety-like behavior and cognitive impairments in a rat model of post-traumatic stress disorder. Behav Brain Res 2016; 311:408-415.
53. Zhang Y, Lu W, Wang Z, Di Z, Wang G, Aa J. Reduced neuronal cAMP in the nucleus accumbens damages blood-brain barrier integrity and promotes stress vulnerability. Biol Psychiatry 2020; 87:526-537.
54. Eglen RM, Bonhaus DW, Johnson LG, Leung E, Clark RD. Pharmacological characterization of two novel and potent 5-HT4 receptor agonists, RS 67333 and RS 67506, in vitro and in vivo. Br J Pharmacol 1995; 115:1387-1392.
55. Bonhaus DW, Loury DN, Jakeman LB, Hsu SA, To ZP, Leung E, et al. [3H]RS-23597-190, a potent 5-hydroxytryptamine4 antagonist labels sigma-1 but not sigma-2 binding sites in guinea pig brain. J Pharmacol Exp Ther 1994; 271:484-493.
56. Wawra M, Fidzinski P, Heinemann U, Mody I, Behr J. 5-HT4-Receptors modulate induction of long-term depression but not potentiation at hippocampal output synapses in acute rat brain slices. PLoS One 2014; 9:e88085.
57. Eriksson T, Delagrange P, Spedding M, Popoli M, Mathé A, Ögren S, et al. Emotional memory impairments in a genetic rat model of depression: involvement of 5-HT/MEK/Arc signaling in restoration. Mol Psychiatry 2012; 17:173-184.
58. Matsumoto M. Evidence for involvement of central 5-HT4 receptors in cholinergic function associated with cognitive processes: behavioral, electrophysiological, and neurochemical studies. J Pharmacol Exp Ther 2001; 296:676–682.
59. Shen F, Smith JAM, Chang R, Bourdet DL, Tsuruda PR, Obedencio GP, et al. 5-HT4 Receptor Agonist Mediated Enhancement of Cognitive Function in vivo and Amyloid Precursor Protein Processing in vitro: A Pharmacodynamic and Pharmacokinetic Assessment. Neuropharmacology 2011; 61:69-79.
60. Lelong V, Lhonneur L, Dauphin F, Boulouard M. BIMU 1 and RS 67333, two 5-HT4 receptor agonists, modulate spontaneous alternation deficits induced by scopolamine in the mouse. Naunyn Schmiedebergs Arch Pharmacol 2003; 367:621-628.
61. Micale V, Leggio GM, Mazzola C, Drago F. Cognitive Effects of SL65.0155, a Serotonin 5-HT4 Receptor Partial Agonist, in Animal Models of Amnesia. Brain Res 2006; 1121: 207-215.
62. Nasehi M, Kafi F, Khakpai F, Zarrindast MR. Involvement of the serotonergic system of the ventral hippocampus (CA3) on amnesia induced by ACPA in mice. Behav Brain Res 2015; 286:356–363.
63. Zarate J, Churruca I, Echevarria E, Casis L, De Jesus ML, Del Burgo LS, et al. Immunohistochemical localization of CB 1 cannabinoid receptors in frontal cortex and related limbic areas in obese Zucker rats: Effects of chronic fluoxetine treatment. Brain Res 2008; 1236:57-72.
64. Daubert EA, Condron BG. Serotonin: A regulator of neuronal morphology and circuitry. Neurosci 2010; 33:424–434.
65. Oz M. Receptor-independent actions of cannabinoids on cell membranes: Focus on endocannabinoids. Pharmacol Ther 2006;111:114-144.
66. Hudson BD, Hébert TE, Kelly ME. Ligand- and heterodimer-directed signaling of the CB(1) cannabinoid receptor. Mol Pharmacol 2010; 77:1-9.
67. Busquets-Garcia A, Bains j, Marsicano G. CB1 Receptor signaling in the brain: Extracting specificity from ubiquity. Neuropsychopharmacol Rev 2018; 43:4 – 20.
68. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54:161–202.
69. Kumar KK, Shalev-Benami M, Robertson MJ, Hongli Hu, Banister SD, Hollingsworth SA, et al. Structure of a signaling cannabinoid receptor 1-g protein complex. Cell 2019; 176:448-458.
70. Bosier B, Muccioli GG, Hermans E, Lambert DM. Functionally selective cannabinoid receptor signalling: Therapeutic implications and opportunities. Biochem Pharmacol 2010; 80:1-12.
71. Heifets BD, Chevaleyre V, Castillo PE. Interneuron activity controls endocannabinoid mediated presynaptic plasticity through calcineurin. PNAS 2008; 105:10250-10255.
72. Celada P, Puig MV, Artigas F. Serotonin modulation of cortical neurons and networks. Front Integr Neurosci 2013; 7:25.
73. Søberg K, Moen LV, Skålhegg BS, Laerdahl JK. Evolution of the cAMP-dependent protein kinase (PKA) catalytic subunit isoforms. PLoS One 2017; 12:1-17.
74. Turu G, Szlo L, Hunyady L. Signal transduction of the CB1 cannabinoid receptor. J Mol Endocrinol 2010; 44:75–85.